High‐affinity urokinase‐derived cyclic peptides inhibiting urokinase/urokinase receptor‐interaction: effects on tumor growth and spread

[1]  N. Schmiedeberg,et al.  Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. , 2002, Journal of medicinal chemistry.

[2]  S. Rabbani,et al.  Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. , 2002, Cancer research.

[3]  N. Harbeck,et al.  Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Sweep,et al.  uPA-Silica-Particles (SP-uPA): A Novel Analytical System to Investigate uPA-uPAR Interaction and to Test Synthetic uPAR Antagonists as Potential Cancer Therapeutics , 2002, Biological chemistry.

[5]  M. Ploug,et al.  Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. , 2001, Biochemistry.

[6]  M. Schmitt,et al.  The uPA/uPA receptor system as a target for tumor therapy. , 2001, Drug news & perspectives.

[7]  N. Harbeck,et al.  Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours , 2001, Expert opinion on biological therapy.

[8]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[9]  A. Krüger,et al.  High Level Synthesis of Recombinant Soluble Urokinase Receptor (CD87) by Ovarian Cancer Cells Reduces Intraperitoneal Tumor Growth and Spread in Nude Mice , 2001, Biological chemistry.

[10]  M. Ploug,et al.  Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy. , 2001, Biochemical Society transactions.

[11]  M. Lamfers,et al.  Adenoviral Expression of a Urokinase Receptor–Targeted Protease Inhibitor Inhibits Neointima Formation in Murine and Human Blood Vessels , 2001, Circulation.

[12]  M. Schmitt,et al.  A Novel Type of Bifunctional Inhibitor Directed against Proteolytic Activity and Receptor/Ligand Interaction , 2000, The Journal of Biological Chemistry.

[13]  N. Harbeck,et al.  New ELISA for quantitation of human urokinase receptor (CD87) in cancer. , 2000, International journal of oncology.

[14]  A. Gown,et al.  A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Mazar,et al.  A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  A. Krüger,et al.  The urokinase plasminogen activator system as a novel target for tumour therapy , 2000 .

[17]  A. Krüger,et al.  Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87) , 2000, Cancer Gene Therapy.

[18]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[19]  S. Zhuo,et al.  Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[20]  M. Schmitt,et al.  Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). , 1998, International journal of oncology.

[21]  N. Harbeck,et al.  Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function , 1998, FEBS letters.

[22]  A. Krüger,et al.  The bacterial lacZ gene: An important tool for metastasis research and evaluation if new cancer therapies , 1998, Cancer and Metastasis Reviews.

[23]  P. Opolon,et al.  Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice , 1998, Gene Therapy.

[24]  N. Mackman,et al.  Binding of Human Single Chain Urokinase to Chinese Hamster Ovary Cells and Cloning of Hamster u-PAR , 1998, Thrombosis and Haemostasis.

[25]  H. Kobayashi,et al.  A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. , 1998, European journal of biochemistry.

[26]  Bonnie F. Sloane,et al.  Cathepsin B and human tumor progression. , 1998, Biological chemistry.

[27]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[28]  S. Goodman,et al.  Stereoisomerism and Biological Activity of the Selective and Superactive αvβ3 Integrin Inhibitor cyclo(-RGDfV-) and Its Retro-Inverso Peptide , 1997 .

[29]  C. Zandonella,et al.  Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. , 1996, Cancer research.

[30]  H. Kobayashi,et al.  Inhibition of metastasis of lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models , 1995, International journal of cancer.

[31]  U. Weidle,et al.  A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. , 1995, Biological chemistry Hoppe-Seyler.

[32]  M. Schmitt,et al.  Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice , 1995, Clinical & Experimental Metastasis.

[33]  D. Rijken.  Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. , 1995, Bailliere's clinical haematology.

[34]  F. Jänicke,et al.  Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. , 1995, Journal of obstetrics and gynaecology.

[35]  A. Petros,et al.  Backbone dynamics of a two-domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator. , 1994, Biochemistry.

[36]  S. Rosenberg,et al.  High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Krüger,et al.  Scattered micrometastases visualized at the single‐cell level: Detection and re‐isolation of lacZ‐labeled metastasized lymphoma cells , 1994, International journal of cancer.

[38]  R. Kreienberg,et al.  Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis. , 1994, British Journal of Cancer.

[39]  A. Levinson,et al.  Prevention of metastasis by inhibition of the urokinase receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[41]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[42]  M. Scully,et al.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. , 1989, The Journal of biological chemistry.

[43]  L. Lund,et al.  One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. , 1988, The Journal of biological chemistry.

[44]  L. Magnelli,et al.  Multiple pathways of cell invasion are regulated by multiple families of serine proteases , 2004, Clinical & Experimental Metastasis.

[45]  Gregg B. Fields,et al.  Peptides for the New Millennium , 2002, American Peptide Symposia.

[46]  N. Schmiedeberg,et al.  Cyclo19,31[D-Cys19]-uPA19-31 Is a Potent Competitive Antagonist of the Interaction of Urokinase-Type Plasminogen Activator with Its Receptor (CD87) , 2001, Biological chemistry.

[47]  U. Weidle,et al.  Inhibition of the Interaction of Urokinase-Type Plasminogen Activator (uPA) with Its Receptor (uPAR) by Synthetic Peptides , 1997, Biological chemistry.